Drug firm Alembic Pharmaceuticals today reported a 35.69 per cent rise in its consolidated net profit to Rs 90.47 crore for the quarter ended June 30 on account of robust sales.
The company had posted a net profit after taxes, non-controlling interests and share of profit of associates and joint ventures of Rs 66.67 crore for the same period of the previous fiscal, Alembic Pharmaceuticals said in a BSE filing.
Consolidated revenue from operations of the company stood at Rs 862.53 crore for the quarter under consideration. It was Rs 648.19 crore for the corresponding period year ago.
Alembic Pharmaceuticals MD Pranav Amin said: "The robust performance in the quarter is attributed to growth across territories. This was led by India formulation business which was impacted by GST transition last year."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app